Skip to main content

Advertisement

SpringerLink
Log in

Pediatric onco-nephrology: time to spread the word

Part I: early kidney involvement in children with malignancy

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Onco-nephrology has been a growing field within the adult nephrology scope of practice. Even though pediatric nephrologists have been increasingly involved in the care of children with different forms of malignancy, there has not been an emphasis on developing special expertise in this area. The fast pace of discovery in this field, including the development of new therapy protocols with their own kidney side effects and the introduction of the CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy, has introduced new challenges for general pediatric nephrologists because of the unique effects of these treatments on the kidney. Moreover, with the improved outcomes in children receiving cancer therapy come an increased number of survivors at risk for chronic kidney disease related to both their cancer diagnosis and therapy. Therefore, it is time for pediatric onco-nephrology to take its spot on the expanding subspecialties map in pediatric nephrology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

    PubMed  Google Scholar 

  2. Ahmed HU, Arya M, Tsiouris A, Sellaturay SV, Shergill IS, Duffy PG, Mushtaq I (2007) An update on the management of Wilms’ tumour. Eur J Surg Oncol 33:824–831

    CAS  PubMed  Google Scholar 

  3. Ahmed HU, Arya M, Levitt G, Duffy PG, Sebire NJ, Mushtaq I (2007) Part II: treatment of primary malignant non-Wilms’ renal tumours in children. Lancet Oncol 8:842–848

    PubMed  Google Scholar 

  4. Rustagi RS, Arora K, Das RR, Pooni PA, Singh D (2017) Incidence, risk factors and outcome of acute kidney injury in critically ill children - a developing country perspective. Paediatr Int Child Health 37:35–41

    PubMed  Google Scholar 

  5. Chawla LS, Eggers PW, Star RA, Kimmel PL (2014) Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371:58–66

    PubMed  Google Scholar 

  6. Park PG, Hong CR, Kang E, Park M, Lee H, Kang HJ, Shin HY, Ha IS, Cheong HI, Yoon HJ, Kang HG (2019) Acute kidney injury in pediatric cancer patients. J Pediatr 208(243–250):e3

    Google Scholar 

  7. Beumer JH, Inker LA, Levey AS (2018) Improving carboplatin dosing based on estimated GFR. Am J Kidney Dis 71:163–165

    PubMed  Google Scholar 

  8. Craig AJ, Samol J, Heenan SD, Irwin AG, Britten A (2012) Overestimation of carboplatin doses is avoided by radionuclide GFR measurement. Br J Cancer 107:1310–1316

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K (1997) Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer 76:1067–1071

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263

    CAS  PubMed  Google Scholar 

  11. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 34:571–590

    CAS  Google Scholar 

  12. Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21:163–167

    CAS  PubMed  Google Scholar 

  13. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953

    CAS  PubMed  Google Scholar 

  14. Renkin EM, Robinson RR (1974) Glomerular filtration. N Engl J Med 290:785–792

    CAS  PubMed  Google Scholar 

  15. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, Muñoz A (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82:445–453

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Grubb A, Lofberg H (1985) Human gamma-trace. Structure, function and clinical use of concentration measurements. Scand J Clin Lab Invest Suppl 177:7–13

    CAS  PubMed  Google Scholar 

  17. Bárdi E, Oláh AV, Bartyik K, Endreffy E, Jenei C, Kappelmayer J, Kiss C (2004) Late effects on renal glomerular and tubular function in childhood cancer survivors. Pediatr Blood Cancer 43:668–673

    PubMed  Google Scholar 

  18. Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D, Kramm CM (2006) Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer 46:767–772

    CAS  PubMed  Google Scholar 

  19. Nilsson-Ehle P, Grubb A (1994) New markers for the determination of GFR: iohexol clearance and cystatin C serum concentration. Kidney Int Suppl 47:S17–S19

    CAS  PubMed  Google Scholar 

  20. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J (1998) Cystatin C--a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101:875–881

    PubMed  Google Scholar 

  21. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A (1999) Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 59:587–592

    CAS  PubMed  Google Scholar 

  22. Tangri N, Stevens LA, Schmid CH, Zhang YL, Beck GJ, Greene T, Coresh J, Levey AS (2011) Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney Int 79:471–477

    CAS  PubMed  Google Scholar 

  23. Naumnik W, Niklinska W, Ossolinska M, Chyczewska E (2009) Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy. Folia Histochem Cytobiol 47:207–213

    CAS  PubMed  Google Scholar 

  24. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G (2009) Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 26:10–15

    CAS  PubMed  Google Scholar 

  25. Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y, Lu G (2011) Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett 2:693–699

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Jones M, Denieffe S, Griffin C, Tinago W, Fitzgibbon MC (2017) Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med 8:95–104

    PubMed  PubMed Central  Google Scholar 

  27. Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalena L, Bogazzi F, Martino E (2005) Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Investig 28:346–349

    CAS  Google Scholar 

  28. Manetti L, Genovesi M, Pardini E, Grasso L, Lupi I, Morselli LL, Pellegrini G, Martino E (2005) Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves’ ophthalmopathy. Clin Chim Acta 356:227–228

    CAS  PubMed  Google Scholar 

  29. Risch L, Herklotz R, Blumberg A, Huber AR (2001) Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 47:2055–2059

    CAS  PubMed  Google Scholar 

  30. Chantler C, Barratt TM (1972) Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:613–617

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Hilson AJ, Mistry RD, Maisey MN (1976) 99Tcm-DTPA for the measurement of glomerular filtration rate. Br J Radiol 49:794–796

    CAS  PubMed  Google Scholar 

  32. Price CP, Finney H (2000) Developments in the assessment of glomerular filtration rate. Clin Chim Acta 297:55–66

    CAS  PubMed  Google Scholar 

  33. Redal-Baigorri B, Stokholm KH, Rasmussen K, Jeppesen N (2011) Estimation of kidney function in cancer patients. Dan Med Bull 58:A4236

    PubMed  Google Scholar 

  34. Grönroos MH, Jahnukainen T, Irjala K, Härkönen R, Hurme S, Möttönen M, Salmi TT (2008) Comparison of glomerular function tests in children with cancer. Pediatr Nephrol 23:797–803

    PubMed  Google Scholar 

  35. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS, British Nuclear Medicine Society (2004) Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun 25:759–769

    PubMed  Google Scholar 

  36. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19–38

    CAS  PubMed  Google Scholar 

  37. Flombaum CD (2000) Metabolic emergencies in the cancer patient. Semin Oncol 27:322–334

    CAS  PubMed  Google Scholar 

  38. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82:160–165

    PubMed  Google Scholar 

  39. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, Endou H, Lipkowitz M, Abramson R, Mu W, Johnson RJ (2005) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25:425–433

    CAS  PubMed  Google Scholar 

  40. Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, Henderson GN, Johnson RJ, Sautin YY (2009) Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 20:545–553

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M (2007) Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 292:F373–F381

    CAS  PubMed  Google Scholar 

  42. Boles JM, Dutel JL, Briere J, Mialon P, Robasckiewicz M, Garre M, Briere J (1984) Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53:2425–2429

    CAS  PubMed  Google Scholar 

  43. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11

    PubMed  Google Scholar 

  44. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network (2007) Acute kidney injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31

    PubMed  PubMed Central  Google Scholar 

  45. Abu-Alfa AK, Younes A (2010) Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 55(5 Suppl 3):S1-13; quiz S4-9

  46. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778

    CAS  PubMed  Google Scholar 

  47. Andreoli SP, Clark JH, McGuire WA, Bergstein JM (1986) Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 109:292–298

    CAS  PubMed  Google Scholar 

  48. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A, Rouvier P (2014) Kidney injuries related to ipilimumab. Investig New Drugs 32:769–773

    CAS  Google Scholar 

  49. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697–704

    CAS  PubMed  Google Scholar 

  50. McCullough PA, Sandberg KR (2003) Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 4(Suppl 5):S3–S9

    PubMed  Google Scholar 

  51. Persson PB, Tepel M (2006) Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 100:S8–s10

    CAS  Google Scholar 

  52. Cicin I, Erdogan B, Gulsen E, Uzunoglu S, Sut N, Turkmen E, Kodaz H, Ustundag S (2014) Incidence of contrast-induced nephropathy in hospitalised patients with cancer. Eur Radiol 24:184–190

    PubMed  Google Scholar 

  53. Hong SI, Ahn S, Lee YS, Kim WY, Lim KS, Lee JH, Lee JL (2016) Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer 24:1011–1017

    PubMed  Google Scholar 

  54. Jeon J, Kim S, Yoo H, Kim K, Kim Y, Park S, Jang HR, Kim DK, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE (2019) Risk prediction for contrast-induced nephropathy in cancer patients undergoing computed tomography under preventive measures. J Oncol 2019:8736163

  55. Seeliger E, Sendeski M, Rihal CS, Persson PB (2012) Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J 33:2007–2015

    PubMed  Google Scholar 

  56. Rosenstock JL, Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40:749–755

    CAS  PubMed  Google Scholar 

  57. Vogt B, Ferrari P, Schönholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, Serra A, Huynh-Do U, Uehlinger D, Frey FJ (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111:692–698

    CAS  PubMed  Google Scholar 

  58. Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179–c184

    PubMed  Google Scholar 

  59. Ad-hoc Working Group of ERBP, Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W (2012) A European renal best practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27:4263–4272

    Google Scholar 

  60. European Society of Urogenital Radiology (2018) Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast. European Society of Urogenital Radiology, Contrast-Media Guidelines 10.0 2018. Available from: http://www.esur.org/esur-guidelines/

  61. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 30:1663–1669

    PubMed  PubMed Central  Google Scholar 

  62. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V (2005) Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 130:67–75

    PubMed  Google Scholar 

  63. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML, Children’s Oncology Group (2008) Factors influencing survival after relapse from acute lymphoblastic leukemia: a children’s oncology group study. Leukemia 22:2142–2150

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL (2011) Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the children’s oncology group. Blood 117:3010–3015

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT (2017) Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45:e124–e131

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Frey NV, Porter DL (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016:567–572

  67. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 19:2048–2060

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3:16011

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15:47–62

    CAS  PubMed  Google Scholar 

  70. Wang HH, Yang AH, Yang LY, Hung GY, Chang JW, Wang CK, Lee TY, Tang RB (2011) Chronic graft-versus-host disease complicated by nephrotic syndrome. J Chin Med Assoc 74:419–422

    PubMed  Google Scholar 

  71. Kersting S, Koomans HA, Hene RJ, Verdonck LF (2007) Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 39:359–365

    CAS  PubMed  Google Scholar 

  72. Parikh CR, Schrier RW, Storer B, Diaconescu R, Sorror ML, Maris MB, Maloney DG, McSweeney P, Storb R, Sandmaier BM (2005) Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 45:502–509

    PubMed  Google Scholar 

  73. Liu D, Yan C, Xu L, Wang Y, Han W, Zhang X, Liu K, Huang X (2010) Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol Blood Marrow Transplant 16:1567–1575

    PubMed  Google Scholar 

  74. Kersting S, Dorp SV, Theobald M, Verdonck LF (2008) Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 14:125–131

    CAS  PubMed  Google Scholar 

  75. Lopes JA, Jorge S, Silva S, de Almeida E, Abreu F, Martins C, do Carmo JA, Lacerda JF, Prata MM (2006) Acute renal failure following myeloablative autologous and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 38:707

    CAS  PubMed  Google Scholar 

  76. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R (2008) Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 36(4 Suppl):S198–S203

    PubMed  Google Scholar 

  77. Parikh CR, Coca SG (2006) Acute renal failure in hematopoietic cell transplantation. Kidney Int 69:430–435

    CAS  PubMed  Google Scholar 

  78. Mori J, Ohashi K, Yamaguchi T, Ando M, Hirashima Y, Kobayashi T, Kakihana K, Sakamaki H (2012) Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on acute kidney injury network criteria. Intern Med 51:2105–2110

    PubMed  Google Scholar 

  79. Higo SSA, Masuda Y, Nagasaka S, Kajimoto Y, Kanzaki G, Fukui M, Nagahama K, Mii A, Kaneko T, Tsuruoka S (2014) Acute graft-versus- host disease of the kidney in allogeneic rat bone marrow transplantation. PLoS One 9:e115399 https://doi.org/10.1371/journal.pone.0115399

    PubMed  PubMed Central  Google Scholar 

  80. Fraile P, Vazquez L, Caballero D, Garcia-Cosmes P, López L, San Miguel J, Tabernero JM (2013) Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol 91:129–134

    PubMed  Google Scholar 

  81. Stylianou K, Stratakis S, Mavroeidi V, Petrakis I, Xydakis D, Vardaki E, Stratigis S, Perakis K, Katsarou T, Kanellou P, Xylouri I, Petraki C, Alexandrakis M, Daphnis E (2010) Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplantation: a case report. J Med Case Rep 4:303

    PubMed  PubMed Central  Google Scholar 

  82. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191–204

    PubMed  Google Scholar 

  83. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124:645–653

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN, Lane A, Wilkey A, Lake KE, Litts B, Davies SM (2017) Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 130:1259–1266

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Béland S, Vallin P, Désy O, Lévesque E, De Serres SA (2017) Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. J Thromb Haemost 15:1020–1031

    PubMed  Google Scholar 

  86. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC, Davies SM, Jodele S (2013) Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 96:217–223

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Warren M, Jodele S, Dandoy C, Myers KC, Wallace G, Nelson A, El-Bietar J (2017) A complete histologic approach to gastrointestinal biopsy from hematopoietic stem cell transplant patients with evidence of transplant-associated gastrointestinal thrombotic Microangiopathy. Arch Pathol Lab Med 141:1558–1566

    CAS  PubMed  Google Scholar 

  88. Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR (2009) Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 4:345–353

    PubMed  PubMed Central  Google Scholar 

  89. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE (2010) Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant 16:515–524

    CAS  PubMed  Google Scholar 

  90. Abboud I, Peraldi MN, Hingorani S (2012) Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. Semin Hematol 49:73–82

    PubMed  Google Scholar 

  91. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 Published May 28, 2009 (v4.03: June 14, 2010). US Department of health and human services, National institutes of health, National cancer institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

  92. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11:571–575

    PubMed  Google Scholar 

  93. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T, European Group for Blood and Marrow Transplantation; European LeukemiaNet (2007) Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group. Haematologica 92:95–100

    PubMed  Google Scholar 

  94. Izzedine H, Brocheriou I, Deray G, Rixe O (2007) Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 22:1481–1482

    PubMed  Google Scholar 

  95. Khansur T, Kennedy A (1991) Case report: cisplatin-induced hemolytic uremic syndrome. Am J Med Sci 301:390–392

    CAS  PubMed  Google Scholar 

  96. Niu J, Mims MP (2012) Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. J Clin Oncol 30:e312–e314

    PubMed  Google Scholar 

  97. Walker RW, Rosenblum MK, Kempin SJ, Christian MC (1989) Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 64:1017–1020

    CAS  PubMed  Google Scholar 

  98. Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F (2012) Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 17:1534–1540

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, Parker PM, Khaled SK, Forman SJ, Nakamura R (2013) Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:298–304

    PubMed  Google Scholar 

  100. Erbey F, Bayram I, Kuskonmaz B, Yilmaz S, Cetin M, Uckan D, Tanyeli A (2010) Thrombotic microangiopathy in allogeneic stem cell transplantation in childhood. Exp Clin Transplant 8:237–244

    PubMed  Google Scholar 

  101. Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J, Mehta PA, Bleesing JJ, Filipovich AH, Marsh RA, Jodele S (2011) Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17:1512–1519

    PubMed  Google Scholar 

  102. Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC (2014) Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93:333–339

    CAS  Google Scholar 

  103. Serke S, Riess H, Oettle H, Huhn D (1999) Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 79:1519–1521

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Saif MW, McGee PJ (2005) Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 6:369–374

    PubMed  Google Scholar 

  105. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS (1989) Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7:781–789

    CAS  PubMed  Google Scholar 

  106. Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, Henry DH, Korec S, Bertram JH, Guthrie TH Jr, Ciavarella D, Wuest D, Perkins W, Balint JP Jr, Cochran SK, Peugeot RL, Jones FR (1993) Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71:1882–1892

    PubMed  Google Scholar 

  107. Siau K, Varughese M (2010) Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol 27:1057–1059

    PubMed  Google Scholar 

  108. Onitilo AA, Engel JM, Clouse LH, Gerndt KM (2009) Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. J Vasc Interv Radiol 20:275–276

    PubMed  Google Scholar 

  109. Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, Iyer RV (2009) Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol 64:177–181

    CAS  PubMed  Google Scholar 

  110. Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P (2013) Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther 7:723–728

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Starck M, Wendtner CM (2014) Thrombotic microangiopathies. Dtsch Med Wochenschr 139:1993–1996

    CAS  PubMed  Google Scholar 

  112. Hausberg M, Felten H, Pfeffer S (2019) Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer. Case Rep Oncol 12:1–6

    PubMed  PubMed Central  Google Scholar 

  113. Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R (2015) Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 83:125–129

    PubMed  Google Scholar 

  114. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM (2014) Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20:518–525

    CAS  PubMed  Google Scholar 

  115. Nishijima Y, Hirata H, Himeno A, Kida H, Matsumoto M, Takahashi R, Otani Y, Inoue K, Nagatomo I, Takeda Y, Kijima T, Tachibana I, Fujimura Y, Kumanogoh A (2013) Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. Intern Med 52:1111–1114

    PubMed  Google Scholar 

  116. Galloway J (1922) Remarks ON HODGKIN'S DISEASE. Br Med J 2:1201–1208

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Lindheimer MD, Davison JM, Katz AI (2001) The kidney and hypertension in pregnancy: twenty exciting years. Semin Nephrol 21:173–189

    CAS  PubMed  Google Scholar 

  118. Levi I, Dinour D, Ben-Bassat I, Raanani P (2002) Acute myeloid leukemia associated with nephrotic syndrome: case report and literature review. Leuk Lymphoma 43:1133–1136

    PubMed  Google Scholar 

  119. Bacchetta J, Juillard L, Cochat P, Droz JP (2009) Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 70:39–58

    PubMed  Google Scholar 

  120. Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD (2009) Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 71:130–139

    CAS  PubMed  Google Scholar 

  121. Sullivan MR, Danilov AV, Lansigan F, Dunbar NM (2015) Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher 30:308–310

    PubMed  Google Scholar 

  122. Rosolem MM, Rabello LS, Lisboa T, Caruso P, Costa RT, Leal JV, Salluh JI, Soares M (2012) Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care 27:301–307

    PubMed  Google Scholar 

  123. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, Dupuis LL, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli S, Steinbach WJ, Villarroel M, Zaoutis T, Sung L, International Pediatric Fever and Neutropenia Guideline Panel (2012) Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 30:4427–4438

    PubMed  Google Scholar 

  124. Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH (2010) Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53–59

    PubMed  Google Scholar 

  125. Klaassen ILM, de Haas V, van Wijk JAE, Kaspers GJL, Bijlsma M, Bökenkamp A (2011) Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 56:868–870

    CAS  PubMed  Google Scholar 

  126. Mori R, Yonemoto N, Fitzgerald A, Tullus K, Verrier-Jones K, Lakhanpaul M (2010) Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy. Acta Paediatr 99:581–584

    CAS  PubMed  Google Scholar 

  127. Thirumala R, Ramaswamy M, Chawla S (2010) Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin 26:59–91

    CAS  PubMed  Google Scholar 

  128. Oh SJ, Ku JH, Byun SS, Lee SW, Jeon HG, Kim HH (2005) Systemic chemotherapy in patients with indwelling ureteral stenting. Int J Urol 12:548–551

    PubMed  Google Scholar 

  129. Vennervald BJ, Polman K (2009) Helminths and malignancy. Parasite Immunol 31:686–696

    CAS  PubMed  Google Scholar 

  130. Barsoum RS (2003) Schistosomiasis and the kidney. Semin Nephrol 23:34–41

    PubMed  Google Scholar 

  131. Bruno B, Zager RA, Boeckh MJ, Gooley TA, Myerson DH, Huang ML, Hackman RC (2004) Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation 77:1049–1057

    PubMed  Google Scholar 

  132. Waldman M, Marshall V, Whitby D, Kopp JB (2008) Viruses and kidney disease: beyond HIV. Semin Nephrol 28:595–607

    PubMed  PubMed Central  Google Scholar 

  133. Teague MW, Glick AD, Fogo AB (1991) Adenovirus infection of the kidney: mass formation in a patient with Hodgkin's disease. Am J Kidney Dis 18:499–502

    CAS  PubMed  Google Scholar 

  134. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO (2011) Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 17:1551–1555

    PubMed  PubMed Central  Google Scholar 

  135. Jacobsen T, Sifontis N (2010) Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 67:1417–1425

    CAS  PubMed  Google Scholar 

  136. Hsieh CL, Lin SY, Huang CC, Liu JH (2010) Cytomegalovirus in the kidney allograft. Intern Med 49:2185

    PubMed  Google Scholar 

  137. Shaffer DR, Rooney CM, Gottschalk S (2010) Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy 2:663–671

    CAS  PubMed  Google Scholar 

  138. Scott RH, Stiller CA, Walker L, Rahman N (2006) Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43:705–715

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA (2011) Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56:7–15

    PubMed  PubMed Central  Google Scholar 

  140. England RJ, Haider N, Vujanic GM, Kelsey A, Stiller CA, Pritchard-Jones K, Powis M (2011) Mesoblastic nephroma: a report of the United Kingdom Children's Cancer and Leukaemia group (CCLG). Pediatr Blood Cancer 56:744–748

    PubMed  Google Scholar 

  141. Vokuhl C, Nourkami-Tutdibi N, Furtwängler R, Gessler M, Graf N, Leuschner I (2018) ETV6-NTRK3 in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study. Pediatr Blood Cancer 65(4)

  142. Rowe RG, Thomas DG, Schuetze SM, Hafez KS, Lawlor ER, Chugh R (2013) Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors. Urology 81:347–353

    PubMed  Google Scholar 

  143. Cajaiba MM, Jennings LJ, George D, Perlman EJ (2016) Expanding the spectrum of ALK-rearranged renal cell carcinomas in children: identification of a novel HOOK1-ALK fusion transcript. Genes Chromosomes Cancer 55:814–817

    CAS  PubMed  PubMed Central  Google Scholar 

  144. Cajaiba MM, Khanna G, Smith EA, Gellert L, Chi YY, Mullen EA, Hill DA, Geller JI, Dome JS, Perlman EJ (2016) Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Hum Pathol 48:81–87

    CAS  PubMed  Google Scholar 

  145. Argani P, Zhang L, Sung YS, Bacchi C, Swanson D, Dickson BC, Antonescu CR (2020) Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma. Genes Chromosomes Cancer 59:203–208

    CAS  PubMed  Google Scholar 

  146. Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA (2014) DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol 27:1267–1280

    CAS  PubMed  PubMed Central  Google Scholar 

  147. Perlman EJ, Faria P, Soares A, Hoffer F, Sredni S, Ritchey M, Shamberger RC, Green D, Beckwith JB, National Wilms Tumor Study Group (2006) Hyperplastic perilobar nephroblastomatosis: long-term survival of 52 patients. Pediatr Blood Cancer 46:203–221

    PubMed  Google Scholar 

  148. Fischbach BV, Trout KL, Lewis J, Luis CA, Sika M (2005) WAGR syndrome: a clinical review of 54 cases. Pediatrics 116:984–988

    PubMed  Google Scholar 

  149. Koziell AB, Grundy R, Barratt TM, Scambler P (1999) Evidence for the genetic heterogeneity of nephropathic phenotypes associated with Denys-Drash and Frasier syndromes. Am J Hum Genet 64:1778–1781

    CAS  PubMed  PubMed Central  Google Scholar 

  150. Barbaux S, Niaudet P, Gubler MC, Grünfeld JP, Jaubert F, Kuttenn F, Fékété CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17:467–470

    CAS  PubMed  Google Scholar 

  151. Garcia-Castillo H, Vasquez-Velasquez AI, Rivera H, Barros-Nunez P (2008) Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: delineation of clinical subtypes. Am J Med Genet A 146A:1687–1695

    PubMed  Google Scholar 

  152. Cairney AE, Andrews M, Greenberg M, Smith D, Weksberg R (1987) Wilms tumor in three patients with bloom syndrome. J Pediatr 111:414–416

    CAS  PubMed  Google Scholar 

  153. Hartley AL, Birch JM, Tricker K, Wallace SA, Kelsey AM, Harris M, Jones PH (1993) Wilms’ tumor in the Li-Fraumeni cancer family syndrome. Cancer Genet Cytogenet 67:133–135

    CAS  PubMed  Google Scholar 

  154. Begum Z, Sharieff S, Attar AH (2013) Familial occurrence of nonsyndromic wilms tumor-a report in two siblings. Indian J Surg 75(Suppl 1):99–102

    PubMed  Google Scholar 

  155. Hyde SM, et al. (1993) CDC73-related disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA)

  156. Hamalainen RH, Joensuu T, Kallijarvi J, Lehesjoki AE (2006) Characterisation of the MULIBREY nanism-associated TRIM37 gene: transcription initiation, promoter region and alternative splicing. Gene 366:180–188

    PubMed  Google Scholar 

  157. Lee H, Khan R, O'Keefe M (2008) Aniridia: current pathology and management. Acta Ophthalmol 86:708–715

    CAS  PubMed  Google Scholar 

  158. Carey JC, Barnes AM (2016) Wilms tumor and trisomy 18: is there an association? Am J Med Genet C Semin Med Genet 172:307–308

    PubMed  Google Scholar 

  159. Morris MR, Astuti D, Maher ER (2013) Perlman syndrome: overgrowth, Wilms tumor predisposition and DIS3L2. Am J Med Genet C Semin Med Genet 163C:106–113

    PubMed  Google Scholar 

  160. Porteus MH, Narkool P, Neuberg D, Guthrie K, Breslow N, Green DM, Diller L (2000) Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms’ tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 18:2026–2031

    CAS  PubMed  Google Scholar 

  161. Chen E, Johnson JP, Cox VA, Golabi M (1993) Simpson-Golabi-Behmel syndrome: congenital diaphragmatic hernia and radiologic findings in two patients and follow-up of a previously reported case. Am J Med Genet 46:574–578

    CAS  PubMed  Google Scholar 

  162. Isidor B, Bourdeaut F, Lafon D, Plessis G, Lacaze E, Kannengiesser C, Rossignol S, Pichon O, Briand A, Martin-Coignard D, Piccione M, David A, Delattre O, Jeanpierre C, Sévenet N, Le Caignec C (2013) Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. Eur J Hum Genet 21:784–787

    CAS  PubMed  Google Scholar 

  163. Abbo O, Pinnagoda K, Brouchet L, Leobon B, Savagner F, Oliver I, Galinier P, Castex MP, Pasquet M (2018) Wilms tumor, pleuropulmonary blastoma, and DICER1: case report and literature review. World J Surg Oncol 16:164

    PubMed  PubMed Central  Google Scholar 

  164. Peterman CM, Fevurly RD, Alomari AI, Trenor CC 3rd, Adams DM, Vadeboncoeur S, Liang MG, Greene AK, Mulliken JB, Fishman SJ (2017) Sonographic screening for Wilms tumor in children with CLOVES syndrome. Pediatr Blood Cancer 64(12)

  165. Lapunzina P (2005) Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet 137C:53–71

    PubMed  Google Scholar 

  166. Muller E II, Hudgins L (1993) 9q22.3 Microdeletion. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K et al (eds) GeneReviews((R)), Seattle (WA)

  167. Bourdeaut F, Guiochon-Mantel A, Fabre M, Martelli H, Patte C, Porta G, Bernard O, Delattre O, Jacquemin E (2008) Alagille syndrome and nephroblastoma: unusual coincidence of two rare disorders. Pediatr Blood Cancer 50:908–911

    PubMed  Google Scholar 

  168. Russell B, Johnston JJ, Biesecker LG, Kramer N, Pickart A, Rhead W, Tan WH, Brownstein CA, Kate Clarkson L, Dobson A, Rosenberg AZ, Vergano SA, Helm BM, Harrison RE, Graham JM Jr (2015) Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. Am J Med Genet A 167A:2122–2131

    PubMed  Google Scholar 

  169. Green DM, Breslow NE, Beckwith JB, Norkool P (1993) Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study. Med Pediatr Oncol 21:188–192

    CAS  PubMed  Google Scholar 

  170. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M (1998) Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 79:274–278

    CAS  PubMed  Google Scholar 

  171. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, Moch H (2004) Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 28:1117–1132

    PubMed  Google Scholar 

  172. Teplick A, Kowalski M, Biegel JA, Nichols KE (2011) Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician. Eur J Pediatr 170:285–294

    PubMed  PubMed Central  Google Scholar 

  173. Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C, Bernstein J (1998) Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol 22:180–187

    CAS  PubMed  Google Scholar 

  174. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R (2010) Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 61:329–343

    CAS  PubMed  PubMed Central  Google Scholar 

  175. Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ (2002) Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 60:1083–1089

    PubMed  Google Scholar 

  176. Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, Geller JI, Ehrlich PF, Cost NG, Dome JS, Fernandez CV, Khanna G (2017) Imaging of renal medullary carcinoma in children and young adults: a report from the children’s oncology group. Pediatr Radiol 47:1615–1621

    PubMed  PubMed Central  Google Scholar 

  177. Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP, Ghavamian R (2007) Renal medullary carcinoma: the Bronx experience. Urology 70:878–882

    PubMed  Google Scholar 

  178. Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ, Routh JC, Rice HE, Tracy ET (2017) Renal medullary carcinoma: a national analysis of 159 patients. Pediatr Blood Cancer 64(11)

  179. Alrashdi I, Levine S, Paterson J, Saxena R, Patel SR, Depani S, Hargrave DR, Pritchard-Jones K, Hodgson SV (2010) Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Familial Cancer 9:239–243

    PubMed  Google Scholar 

  180. Wilson CL, Ness KK, Neglia JP, Hammond S, Shnorhavorian M, Leisenring WL, Stovall M, Robison LL, Armstrong GT (2013) Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 105:504–508

    PubMed  PubMed Central  Google Scholar 

  181. Schafernak KT, Yang XJ, Hsueh W, Leestma JL, Stagl J, Goldman S (2007) Pediatric renal cell carcinoma as second malignancy: reports of two cases and a review of the literature. Can J Urol 14:3739–3744

    PubMed  Google Scholar 

  182. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer Care (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer care. Cancer Chemother Pharmacol 61:903–909

    CAS  PubMed  Google Scholar 

  183. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1–10

    CAS  PubMed  Google Scholar 

  184. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703

    CAS  PubMed  Google Scholar 

  185. Chauvet S, Courbebaisse M, Ronco P, Plaisier E (2014) Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol 82:402–406

    CAS  PubMed  Google Scholar 

  186. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A, Rouvier P (2014) Kidney injuries related to ipilimumab. Invest New Drugs 32:769–773

    CAS  PubMed  Google Scholar 

  187. Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. United Kingdom Children’s Cancer study group. Br J Cancer 82:1636–1645

    CAS  PubMed  PubMed Central  Google Scholar 

  188. Nissim I, Horyn O, Daikhin Y, Nissim I, Lazarow A, Yudkoff M (2002) Regulation of urea synthesis by agmatine in the perfused liver: studies with 15N. Am J Physiol Endocrinol Metab 283:E1123–E1134

    CAS  PubMed  Google Scholar 

  189. Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, Yudkoff M (2006) Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 66:7824–7831

    CAS  PubMed  Google Scholar 

  190. Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, Iyer R (2014) Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 5:E30–E33

    PubMed  PubMed Central  Google Scholar 

  191. Valavaara R, Nordman E (1985) Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 55:47–50

    CAS  PubMed  Google Scholar 

  192. Rollino C, Beltrame G, Ferro M, Quattrocchio G, Tonda L, Quarello F (2010) Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors. G Ital Nefrol 27(Suppl 50):S70–S74

    PubMed  Google Scholar 

  193. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y (2013) Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 75:919–930

    CAS  PubMed  Google Scholar 

  194. Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC (2010) Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73:213–219

    PubMed  Google Scholar 

  195. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127–145

    CAS  PubMed  Google Scholar 

  196. Sawyer MH, Webb DE, Balow JE, Straus SE (1988) Acyclovir-induced renal failure. Clinical course and histology. Am J Med 84:1067–1071

    CAS  PubMed  Google Scholar 

  197. Perazella MA (1999) Crystal-induced acute renal failure. Am J Med 106:459–465

    CAS  PubMed  Google Scholar 

  198. Deray G, Katlama C, Dohin E (1990) Prevention of foscarnet nephrotoxicity. Ann Intern Med 113:332

    CAS  PubMed  Google Scholar 

  199. Izzedine H, Launay-Vacher V, Deray G (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45:804–817

    CAS  PubMed  Google Scholar 

  200. Laniado-Laborin R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26:223–227

    PubMed  Google Scholar 

  201. Atsmon J, Dolev E (2005) Drug-induced hypomagnesaemia : scope and management. Drug Saf 28:763–788

    CAS  PubMed  Google Scholar 

  202. Goldman RD, Koren G (2004) Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 26:421–426

    PubMed  Google Scholar 

  203. Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393

    CAS  PubMed  Google Scholar 

  204. Ejaz P, Bhojani K, Joshi VR (2004) NSAIDs and kidney. J Assoc Physicians India 52:632–640

    CAS  PubMed  Google Scholar 

  205. Andreoli SP (2002) Acute renal failure. Curr Opin Pediatr 14:183–188

    PubMed  Google Scholar 

  206. Hodoshima N, Nakano Y, Izumi M, Mitomi N, Nakamura Y, Aoki M, Gyobu A, Shibasaki S, Kurosawa T (2004) Protective effect of inactive ingredients against nephrotoxicity of vancomycin hydrochloride in rats. Drug Metab Pharmacokinet 19:68–75

    CAS  PubMed  Google Scholar 

  207. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E (2009) Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 111:356–365

    CAS  PubMed  Google Scholar 

  208. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH (2005) Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 97:325–332

    CAS  PubMed  Google Scholar 

  209. Nolin TD, Himmelfarb J (2010) Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol 2010:111–130

  210. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4:481–508

    CAS  PubMed  Google Scholar 

  211. Alappan R, Perazella MA, Buller GK (1996) Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 124:316–320

    CAS  PubMed  Google Scholar 

  212. Mori H, Kuroda Y, Imamura S, Toyoda A, Yoshida I, Kawakami M, Tabei K (2003) Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 42:665–669

    CAS  PubMed  Google Scholar 

  213. Boles JM, Dutel JL, Briere J, Mialon P, Robasckiewicz M, Garre M, Briere J (1984) Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53:2425–2429

    CAS  PubMed  Google Scholar 

  214. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31

    PubMed  PubMed Central  Google Scholar 

  215. Abu-Alfa AK, Younes A (2010) Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 55(5 Suppl 3):S1-13; quiz S4-9

  216. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778

    CAS  PubMed  Google Scholar 

  217. Persson PB, Tepel M (2006) Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 2006:S8–S10

  218. Seeliger E, Sendeski M, Rihal CS, Persson PB (2012) Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J 33:2007–2015

    PubMed  Google Scholar 

  219. Rosenstock JL, Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40:749–755

    CAS  PubMed  Google Scholar 

  220. Deray G (2006) Dialysis and iodinated contrast media. Kidney Int Suppl 2006:S25–S29

  221. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59:222–228

    CAS  PubMed  Google Scholar 

  222. Castillo JJ, Vincent M, Justice E (2012) Diagnosis and management of hyponatremia in cancer patients. Oncologist 17:756–765

    PubMed  PubMed Central  Google Scholar 

  223. Shibata H (2010) Cancer and electrolytes imbalance. Gan To Kagaku Ryoho 37:1006–1010

    CAS  PubMed  Google Scholar 

  224. Lameire N, Van Biesen W, Vanholder R (2010) Electrolyte disturbances and acute kidney injury in patients with cancer. Semin Nephrol 30:534–547

    CAS  PubMed  Google Scholar 

  225. Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152–156

  226. Deheinzelin D, Negri EM, Tucci MR, Salem MZ, da Cruz VM, Oliveira RM, Nishimoto IN, Hoelz C (2000) Hypomagnesemia in critically ill cancer patients: a prospective study of predictive factors. Braz J Med Biol Res 33:1443–1448

    CAS  PubMed  Google Scholar 

  227. Mallouk A, Pham PT, Pham PC (2006) Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 10:284–289

    PubMed  Google Scholar 

  228. Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer N Engl J Med 352:373–379

    CAS  PubMed  Google Scholar 

  229. Cotant CL, Rao PS (2007) Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. Am J Kidney Dis 50:1033–1036

    CAS  PubMed  Google Scholar 

Download references

Answers

1; c 2; d 3; e 4; c 5; b

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Pediatrics, Le Bonheur Children’s Hospital & Saint Jude Research Hospital, The University of Tennessee Health Science Center, TN, Memphis, USA

    Arwa Nada

  2. Division of Nephrology, Department of Pediatrics, Stead Family Children’s Hospital, The University of Iowa, IA, Iowa, USA

    Jennifer G Jetton

Authors
  1. Arwa Nada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer G Jetton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arwa Nada.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Disclosure

All figures were created with BioRender.com.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nada, A., Jetton, J.G. Pediatric onco-nephrology: time to spread the word. Pediatr Nephrol 36, 2227–2255 (2021). https://doi.org/10.1007/s00467-020-04800-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-020-04800-3

Keywords

Search

Navigation